Hughes Report: Second Anniversary

Lizzi Collinge Excerpts

Wednesday 11th February 2026 Westminster Hall

[Lizzi Collinge (Morecambe and Lunesdale) (Lab)]

It is a pleasure to serve here today under your chairship, Ms Allin-Khan. I thank the hon. Member for Chesham and Amersham (Sarah Green) for securing this important debate.

I am going to focus on sodium valproate, which was prescribed for decades without proper warnings about the effect on unborn children. As a result, those children were harmed and, despite multiple Government-commissioned reports, families are still waiting for accountability and redress. Two years on from the Hughes report, that delay can no longer be justified.

Sodium valproate is a medicine used to treat epilepsy and bipolar disorder. It is a very effective medicine for many but, if taken while pregnant, it can cause serious harm. Those harms include major physical birth defects, developmental delays, learning disabilities and a significantly increased risk of autism. Many of the children affected will need lifelong care.

For years, despite those risks being known, women and prescribers were not given clear or adequate information about them. Even after the effects were more widely known, prescriptions continued without proper safeguards in place. At least 7,000 children have been affected by this medicine since it came on to the market in 1973, but the real number is quite likely very much higher because of the lack of awareness around foetal valproate spectrum disorder.

My constituent Nicola was one of the many women affected. Her children were profoundly harmed by exposure during pregnancy. Like so many others, Nicola trusted her doctor and followed proper medical advice. She was badly let down. She has explained to me just how immense the impact has been on her and her children and, of course, what a difference compensation would make to her kids’ lives.

[Luke Myer (Middlesbrough South and East Cleveland) (Lab)]

My hon. Friend is making a passionate case for her constituent. My constituent Gill has told me how she has suffered for around 11 years as a result of the pelvic mesh scandal. She is a member of the Sling the Mesh group. Does my hon. Friend agree that, whether on sodium valproate or pelvic mesh, such groups deserve to be listened to, and that we should pay tribute to them for campaigning for these courageous women?

[Lizzi Collinge]

My hon. Friend is absolutely right. This scandal follows a pattern that we have seen far too many times before: early warnings ignored, information withheld or downplayed, measures to protect people not effectively enacted, and public bodies closing ranks rather than being open and honest when things go wrong. I have done a lot of work on maternity safety, and I have seen those patterns again and again; the parallels are really clear. Had concerns been properly addressed at the outset, so much harm could have been avoided, and so many more children would not have been born with lifelong, preventable conditions.

Their families have been waiting for far too long. There were initial recommendations for redress six years ago in the Cumberlege review, but the previous Government failed to act. Through the Hughes report, we have an even more comprehensive examination of what needs to be done to support those families, but they are no closer to getting even a formal response to that. That constant delay increases the cost, delays support and builds up ill-will with affected families, who have already spent their lives fighting for their kids.

I urge the Government to provide an interim payment for those families. We know that that is possible; Dr Hughes has outlined how to do it in this case, and we have seen it in the infected blood scandal. The main question for the Minister is this: when will we get a full response to the Hughes report? When will we actually see some action?

Like so many of my colleagues, I pay tribute to Emma and Janet from the Independent Fetal Anti-convulsant Trust, who are here today. Their children were affected by sodium valproate, and they have been tireless campaigners for compensation for affected families—I have known them for many years now. They have been invaluable in raising awareness about foetal valproate spectrum disorder. I also thank my hon. Friend the Member for Lancaster and Wyre (Cat Smith), who has worked with In-FACT for many years on this and has been a staunch advocate for their campaign.

Despite all their hard work, progress from the Government’s side seems to have stalled yet again, and families are left waiting. We know that things go wrong in medicine, and that all drugs have side effects, but when a harm that is caused was preventable, and when the state fails to act on warnings, the Government must step up. We should do what we should have done years ago, and give justice and support to the families who have already paid a heavy price for our failings.

[Dr Rosena Allin-Khan (in the Chair)]

I remind Members that it is discourteous not to attend for the opening speeches and then to make interventions. As a result, those Members who have been here from the start and will be here until the end will now have a shorter time limit imposed on them. Because of the number of Members who have indicated that they wish to speak, with the authority of the Chairman of Ways and Means, I am imposing a time limit on Back-Bench speeches of three and a half minutes.